Log In
Print
BCIQ
Print
Print this Print this
 

RG2833

  Manage Alerts
Collapse Summary General Information
Company BioMarin Pharmaceutical Inc.
DescriptionSelective histone deacetylase 3 (HDAC3) inhibitor
Molecular Target Histone deacetylase 3 (HDAC3)
Mechanism of ActionHistone deacetylase 3 (HDAC3) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationAtaxia
Indication DetailsTreat Friedreich's ataxia (FRDA)
Regulatory Designation

U.S. - Orphan Drug (Treat Friedreich's ataxia (FRDA))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today